INS and Hyperglycemia: Among patients with hyperglycemia, clinically meaningful hyperglycemia response (defined ad-hoc as ≥ 0.5% decrease in HbA1c, normalization or ≥ 50mg/dl decrease in 2h plasma glucose on OGTT or decrease in daily insulin or sulfonylurea dose by 25% and 50%, respectively) was observed in 2 of the 13 patients in the low-dose group and 6 of the 12 patients in the high-dose group.